Dr. Martens Shares Slide 16.8% After Boot Sales Fall 20%

Dr. Martens shares fell 16.8% on Thursday, closing at GBX 54.10, after the bootmaker reported a 9.2% year-on-year revenue decline to £292.4 million. The stock lost GBX 10.90 on the day, with 121,855,430 shares traded against an average volume of 6,573,813. The market has rendered its verdict on the first half, and the verdict was not gentle.

The company reported a loss of GBX 1 per share for the quarter, according to Digital Look Earnings. Adjusted EBIT (earnings before interest and taxes, a pre-financing profit measure) swung to a £2.2 million loss from a £3.1 million profit a year earlier. Return on equity stood at 6.89% and net margin at 3.11%, on revenue of £290.40 million.

Where did the damage come from?

The decline concentrated in Europe and direct-to-consumer channels. Boot sales fell 20%, which management attributed to unusually hot weather alongside ongoing pressure on core styles. Heat, it turns out, is unkind to an eight-eyelet boot.

Gross margin offered some consolation, rising 80 basis points on a comparable basis to 65.4%. Operating costs benefited from prior cost actions. Management said margin should remain resilient, though some first-half benefits may ease in the second half.

The balance sheet held its ground. Debt remained broadly flat year over year at £158.9 million, with covenant net debt to EBITDA at 2.2 times against a 3.0-times limit. Cash generation was seasonally negative by £66.2 million as the company built working capital ahead of peak trading.

What is management doing about it?

The company reported encouraging early responses to three initiatives:

• The "With Bouncing Soles" campaign
• Upgraded Brand Centres
• A new Spring/Summer sandals range

Management cautioned that the campaign and store results are still early, and that the new e-commerce platform has required time to bed in. Encouragement, at this stage, remains a qualitative quantity.

Second-half performance is pivotal. Management expects boots to remain a headwind for the rest of FY 2027, with core boot styles still under pressure, and said the business is focused on the key trading weeks ahead. Full-price mix priorities in the UK and DACH (the German-speaking markets of Germany, Austria and Switzerland) are weighted to the second half.

How do the numbers stack up?

Dr. Martens carries a current ratio of 2.61, a quick ratio of 1.13 and a debt-to-equity ratio of 108.85. The firm has a market capitalisation of £517.88 million, a price-to-earnings ratio of 22.54, a PEG ratio of 6.40 and a beta of 0.26. Its 50-day moving average stands at GBX 67.13 and its 200-day moving average at GBX 69.53. The shares have traded between a one-year low of GBX 52.10 and a one-year high of GBX 90.

What are insiders and analysts doing?

In insider activity, Ije Nwokori sold 209,160 shares on Friday, October 16th, at an average price of GBX 69, for a total value of £144,320.40. Over the last 90 days, insiders acquired 927 shares valued at $59,965. Corporate insiders own 2.97% of the company's stock.

Berenberg Bank reissued a "buy" rating and a GBX 110 price target in a report on Friday, October 9th. Two analysts rate the stock a Buy and one a Hold. According to MarketBeat, the consensus rating is "Moderate Buy" with a consensus price target of GBX 105.

Dr. Martens, founded in Northamptonshire, England, produced its first silhouette, the 1460 boot, on 1 April 1960. The brand now operates in more than 60 countries and employs around 3,600 people. Six decades of heritage did not prevent a sixteen-percent single-session decline. The second half must now do the heavy lifting.